OptiBiotix Health plc
("OptiBiotix" or the "Company")
LP-LDL® news media interest in USA
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has become aware of news reports on its LP-LDL® product in the USA. The media interest has been generated by a potential commercial partner, Seed Health, who have purchased LP-LDL® for use in its multi-strain product which is intended for launch in the USA in May 2018.
Seed have developed an innovative product concept which combines multiple strains of different probiotics which have been selected because of strong clinical trial data. The news report refers to clinical studies published in the scientific journal PLOS One ("PLOS") showing that one of the probiotics contained in Seeds multi-strain product reduced LDL or "bad" cholesterol and increased HDL or "good" cholesterol.
OptiBiotix reported (RNS: 7 April 2016) and subsequently published the results of its human studies in PLOS in December 2017 and at international conferences demonstrating statistical and clinical significant reductions in cholesterol and blood pressure. These presentations and publications won best scientific publications at both ProBiota 2017 and ProBiota 2018, and have raised OptiBiotix's international profile, attracting strong commercial interest in LP-LDL®.
The article in Business Insider US provides a link to OptiBiotix's publication and discloses the use of LP-LDL® in Seeds product. OptiBiotix can confirm it is in discussions with Seed to agree commercial terms for the use of its LP-LDL® strain in Seeds products in preparation for a May launch in the USA. Whilst these negotiations are at an advanced stage, they are one of a number of discussions with US partners which may or may not progress to legal agreement. If or when commercial terms are concluded, a further announcement with be made.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased that the strong science, successful human studies and international awards at major scientific conferences have attracted international commercial and media interest in LP-LDL®. This has allowed OptiBiotix to sign manufacturing, formulation/application and distribution partnerships with fast growing companies with leading market positions in multiple industry sectors across the world. We look forward to the opportunity of announcing deals with similar partners in the fast growing US marker once these have been concluded."
For further information, please contact:
OptiBiotix Health plc |
www.optibiotix.com |
Stephen O'Hara, Chief Executive |
Contact via Walbrook below |
|
|
Cairn Financial Advisers LLP (NOMAD) |
Tel: 020 7213 0880 |
Liam Murray / Jo Turner |
|
finnCap (Broker) |
Tel: 020 7220 0500 |
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance) |
|
Abigail Wayne (Corporate Broking) |
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or [email protected] |
Anna Dunphy |
Mob: 07876 741 001 |
|
|
|
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
